David Kerr
Founder at Oxford Cancer Biomarkers Ltd.
David Kerr active positions
Companies | Position | Start | End |
---|---|---|---|
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | Corporate Officer/Principal | - | - |
University of Oxford | Corporate Officer/Principal | - | - |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - | - |
Founder | 2011-12-31 | - | |
Chief Tech/Sci/R&D Officer | 2011-12-31 | - | |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Chief Tech/Sci/R&D Officer | - | - |
Director/Board Member | - | - | |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | Director/Board Member | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Career history of David Kerr
Statistics
International
United Kingdom | 5 |
Cayman Islands | 2 |
Operational
Chief Tech/Sci/R&D Officer | 3 |
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectoral
Health Services | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Health Technology |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | Health Technology |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | Health Services |
- Stock Market
- Insiders
- David Kerr
- Experience